Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to its Immuno-Oncology Scientific Advisory Board

by bizlift | Oct 22, 2019 | Compass Press Releases, Portfolio News

TCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires

by bizlift | Sep 3, 2019 | Compass Press Releases, Portfolio News

Compass Therapeutics Appoints Julie Sunderland to Board of Directors

by bizlift | Aug 1, 2019 | Compass Press Releases, Portfolio News

Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471

by bizlift | Jul 8, 2019 | Compass Press Releases, Portfolio News

Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471

by bizlift | Jun 17, 2019 | Compass Press Releases, Portfolio News

COMPASS THERAPEUTICS ANNOUNCES PRECLINICAL DATA ON LEAD ANTIBODY PROGRAM AND NK CELL ENGAGER PLATFORM TO BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING

by bizlift | Nov 6, 2018 | Compass Press Releases, Portfolio News